Table 3.

Progression-free survival (PFS) and overall survival (OS) between patients with pathogenic or likely pathogenic (P/LP) alterations compared with those with VUS

	P/LP* n=46	VUS n=55
PFS
Median PFS, months (95% CI)	8.4 (5.2 to 23)	3.4 (2.8 to 4.3)
6-month PFS (95% CI)†	0.59 (0.47 to 0.73)	0.27 (0.17 to 0.45)
12-month PFS (95% CI)†	0.46 (0.34 to 0.61)	0.10 (0.04 to 0.27)
HR (95% CI)	0.42 (0.26 to 0.68), p=0.0003	Reference (1.0)
OS
Median OS, months	15.5 (10.3 to 25.1)	9.5 (7.6 to 21.3)
6-month OS (95% CI)†	0.71 (0.60 to 0.84)	0.73 (0.6 to 0.87)
12-month OS (95% CI)†	0.58 (0.46 to 0.73)	0.39 (0.26 to 0.57)
HR (95% CI)	0.62 (0.39 to 1.01), p=0.053	Reference (1.0)

*P/LP show similar proportions and are combined.

†Proportion.

VUS, variants of unknown significance.